The European Cancer Stem Cell Research Institute is an international leader in the field of cancer stem cell research.
Launched in 2011 as one of Cardiff University’s flagship research institutes, the European Cancer Stem Cell Research Institute was established to focus on understanding the biological relationships between stem cells, cancer and cancer stem cells, with the ultimate aim of developing new therapies that can make a real difference to the lives of cancer patients.
The Institute is a collaborative cross-School initiative led by the School of Biosciences, and provides a hi-tech, innovative research environment in which senior academics, researchers and postgraduate students can collaborate. Early career Research Fellows, supported by University and external investment, work alongside world-leading teams in basic biomedical science and translational drug development to help create a UK-based hub of research excellence that aims to revolutionise the way we think about and treat cancer.
The purpose-built Institute is the only centre in Europe completely focused on cancer stem cell research. As a member of the Wales Cancer Research Centre and Wales Cancer Partnership, the Institute is also an integral part of the Cardiff cancer research community, and the new Director is expected to play an important role in shaping future developments in the cancer research landscape both in Cardiff and beyond.
Recognising the advantages that shared learning can offer, we have developed successful, productive partnerships within the Institute, the College of Biological and Life Sciences, the wider University and further afield, both nationally and internationally.
This commitment to collaboration is embedded throughout the Institute, and our joint research with the School of Pharmacy and Pharmaceutical Sciences, the School of Medicine, and CRUK, amongst others, continues to yield exciting results.
We also recognise the importance of strong partnerships with clinical colleagues at the University Hospital Wales and Velindre Cancer Centre, as well as industrial colleagues at, for instance, AstraZeneca and Tiziana Life Sciences.
Please note that the deadline for all applications to be received is the 9th September 2017 and that interviews will be held around the week commencing 9th October 2017 – subject to panel availability.
The Institute provides a hi-tech, innovative research environment”